Last updated 9 months ago

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

1244 patients around the world
Available in Brazil, Argentina, United States, Chile, Colombia
Merck Sharp & Dohme Corp.
21Research sites
1244Patients around the world
This study is for people with
Prostate cancer
Castration resistant prostate cancer
Requirements for the patient
From 18 Years
Male
Medical requirements
Sites
Centro Médico Privado CEMAIC - Córdoba
Centro Médico Privado CEMAIC - Córdoba
Recruiting
Monseñor Pablo Cabrera 2941, Córdoba
Instituto de Investigaciones Clínicas Mar del Plata
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Av. Colón 3456, Mar del Plata, Buenos Aires
Instituto de Oncología de Rosario - IOR
Recruiting
Córdoba 2457, Rosario, Santa Fe
Hospital Alemán
Recruiting
Av. Pueyrredón 1640, CABA, Buenos Aires
CDU - Centro de Urología - Buenos Aires
Recruiting
Av. Córdoba 2424, CABA, Buenos Aires
Sanatorio Parque - Rosario
Recruiting
Boulevard Oroño 860, Rosario, Santa Fe
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Av. Crámer 1180, CABA, Buenos Aires
Centro de Oncología e Investigación Buenos Aires COIBA
Recruiting
Calle 12 Nro 4756, Berazategui, Buenos Aires
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
Manzano 343, Recoleta, Región Metropolitana, Santiago
Oncocentro APYS - Valparaíso
Recruiting
Avenida La Marina 1702, Viña del Mar, Valparaíso
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy